After a dismal show over the previous few quarters, a beat in Q4 is reassuring – despite continued headwinds from companion diagnostic co-development projects, the molecular diagnostic segment turned black driven by robust demand for consumables. Though negative, momentum also improved in China, with normalisation expected towards the end of FY20. Interestingly, margin also inched higher – led by change in NGS strategy and efficiency measures – with further upside potential
06 Feb 2020
Q4 19 profitability beat reassuring FY20 guidance
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q4 19 profitability beat reassuring FY20 guidance
After a dismal show over the previous few quarters, a beat in Q4 is reassuring – despite continued headwinds from companion diagnostic co-development projects, the molecular diagnostic segment turned black driven by robust demand for consumables. Though negative, momentum also improved in China, with normalisation expected towards the end of FY20. Interestingly, margin also inched higher – led by change in NGS strategy and efficiency measures – with further upside potential